Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Long-Term Investors

Fulcrum Therapeutics discontinued its pociredir sickle-cell-disease program after the FDA concluded that PRC2-targeting therapies carry an equivalent malignancy risk, leaving no viable regulatory path for further development. FULC shares fell $3.28, or 51.09%, from $6.42 on June 1 to $3.14 on June 2, 2026. Kaplan Fox & Kilsheimer is investigating potential securities-law violations related to the disclosure and subsequent loss.

Analysis

The relevant investable event is not the plaintiff-firm inquiry but the loss of a major pipeline option and the FDA's apparent mechanism-wide safety stance. FULC should now trade primarily on cash runway, the probability-adjusted value of its remaining programs, and restructuring discipline; absent a near-term, differentiated clinical catalyst, the stock risks shifting from a development multiple to a cash-value framework over the next 1-3 months. The key diligence items are quarter-end cash, annual operating burn, termination costs, and whether management revises headcount or capital-allocation plans.

Second-order read-through is negative for companies whose assets depend on PRC2-complex inhibition, particularly where the safety database is immature or the mechanism is positioned for chronic use. Conversely, companies with non-PRC2 approaches in sickle-cell disease or adjacent rare-hematology indications could benefit from reduced competitive intensity, but only if their own benefit-risk profile is differentiated; this is not a blanket positive for the sector. The legal investigation itself is low-information and should not be treated as an incremental fundamental catalyst unless discovery reveals that management possessed materially different FDA feedback before the discontinuation.

Contrarianly, a post-collapse FULC short may be crowded: if net cash approaches a meaningful portion of market capitalization, downside becomes capped by liquidation value and strategic optionality around remaining assets. A tradable rebound would require explicit cash-preservation actions or credible external validation of the residual pipeline, not merely class-action headlines. Thesis is falsified bearish by a cash runway materially beyond 24 months plus a partner-funded development pathway; it is reinforced by a burn-rate increase, impairment/restructuring charges, or further regulatory constraints on remaining programs over the next two earnings cycles.

Key Decisions for Investors

• Do not initiate a directional position solely on the litigation announcement; treat it as non-fundamental noise unless a complaint identifies new, documentable evidence of prior FDA disclosure failures.
• Maintain a 1-3 month short/watch bias on FULC only after calculating net cash per share and borrow availability. Target downside is a move toward an appropriate cash-minus-wind-down-cost valuation; cover if enterprise value becomes de minimis or management announces a funded partnership/restructuring that extends runway beyond 24 months.
• For biotech books, screen PRC2-inhibitor and epigenetic-oncology exposures for FDA language, chronic-treatment duration, and malignancy-monitoring protocols; reduce names where valuation assumes broad label expansion before regulatory feedback is independently clarified.
• Set alerts for FULC's next earnings release: cash balance, quarterly operating burn, severance/termination charges, remaining-program timelines, and any strategic-review language are the near-term catalysts that determine whether the equity is a residual-asset call option or a further dilution candidate.